Earnings Call Summary | ImmuCell(ICCC.US) Q1 2024 Earnings Conference
The following is a summary of the ImmuCell Corporation (ICCC) Q1 2024 Earnings Call Transcript:Financial Performance:ImmuCell's Q1 2024 product sales have seen a significant jump of 111% compared to Q
ImmuCell Corporation (ICCC) Q1 2024 Earnings Call Transcript
ImmuCell Corporation (ICCC) Q1 2024 Earnings Call Transcript
ImmuCell Reports $7.3M In Product Sales For Quarter Ended March 31, 2024
ImmuCell Reports $7.3M In Product Sales For Quarter Ended March 31, 2024
ImmuCell | 10-Q: Quarterly report
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024
ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2024.
Press Release: ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024 PORTLAND, Maine, May 14, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company")
Immucell 1Q Loss $438,000 >ICCC
Immucell 1Q Loss $438,000 >ICCC
ImmuCell Anticipates No Change To Preliminary Sales Results For Q1 Ended March 31, 2024 That Were Disclosed On April 9
ImmuCell Anticipates No Change To Preliminary Sales Results For Q1 Ended March 31, 2024 That Were Disclosed On April 9
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2024
Conference Call Scheduled for Wednesday, May 15, 2024 at 9:00 AM ETPORTLAND, Maine, May 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing anim
ImmuCell Reports Preliminary Q1 Sales, Stock Climbs 7%
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersJaguar Health (NASDAQ:JAGX) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. aTyr Pharma (NASDAQ:LIFE) shares rose 10.45% to $
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024
ImmuCell Corporation (Nasdaq: ICCC) today announced preliminary, unaudited sales results for the first quarter of 2024, which ended March 31, 2024.
ImmuCell Shares Fall After $20 Million Mixed Securities Shelf Filing
ImmuCell (ICCC) shares dropped 2.3% in recent Tuesday trading, a day after the company filed a registration statement for the potential sale of $20 million of securities. The regulatory shelf filing c
ImmuCell Files for $20M Mixed Shelf Offering
Earnings Call: ImmuCell Sees Recovery in Q4 Amid 2023 Challenges
ImmuCell Corporation (NASDAQ:ICCC) Q4 2023 Earnings Call Transcript
Earnings Call Summary | ImmuCell(ICCC.US) Q4 2023 Earnings Conference
The following is a summary of the ImmuCell Corporation (ICCC) Q4 2023 Earnings Call Transcript:Financial Performance:ImmuCell reported a decline in sales by 6% year on year due to several process chal
ImmuCell Q4 2023 EPS $(0.15) Up From $(0.22) YoY; Product Sales $5.1M Up From $3.9M YoY
ImmuCell Q4 2023 EPS $(0.15) Up From $(0.22) YoY; Product Sales $5.1M Up From $3.9M YoY
ImmuCell GAAP EPS of -$0.15, Revenue of $5.09M
Immucell 4Q Loss $1.14M >ICCC
Immucell 4Q Loss $1.14M >ICCC
No Data